Author:
S. Espindola Milena,M. Habiel David,Lucia Coelho Ana,Parimon Tanyalak,Chen Peter,Mikels-Vigdal Amanda,M. Hogaboam Cory
Publisher
Sciscan Publishing Limited
Reference30 articles.
1. 1. Cox TR, Erler JT. Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. Dis. Model Mech. 2011, 4, 165-178.
2. 2. Decitre M, Gleyzal C, Raccurt M, Peyrol S, Aubert-Foucher E, Csiszar K, et al. Lysyl oxidase-like protein localizes to sites of de novo fibrinogenesis in fibrosis and in the early stromal reaction of ductal breast carcinomas. Lab. Invest. 1998, 78, 143-151.
3. 3. Vadasz Z, Kessler O, Akiri G, Gengrinovitch S, Kagan HM, Baruch Y, et al. Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2. J. Hepatol. 2005, 43, 499-507.
4. 4. Puente A, Fortea JI, Cabezas J, Arias Loste MT, Iruzubieta P, Llerena S, et al. LOXL2-A New Target in Antifibrogenic Therapy? Int. J. Mol. Sci. 2019, 20, 1634.
5. 5. Ikenaga N, Peng ZW, Vaid KA, Liu SB, Yoshida S, Sverdlov DY, et al. Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal. Gut 2017, 66, 1697-1708.